Field evaluation of a sing-dose bivalent vaccine of porcine circovirus type 2b and Mycoplasma hyopneumoniae.

Szczegóły
Abstrakt

Tytuł:: Field evaluation of a sing-dose bivalent vaccine of porcine circovirus type 2b and Mycoplasma hyopneumoniae.
Autorzy:: Yang S; College of Veterinary Medicine, Department of Veterinary Pathology, Seoul National University, Seoul, Republic of Korea.
Ahn Y; College of Veterinary Medicine, Department of Veterinary Pathology, Seoul National University, Seoul, Republic of Korea.
Oh T; College of Veterinary Medicine, Department of Veterinary Pathology, Seoul National University, Seoul, Republic of Korea.
Cho H; College of Veterinary Medicine, Department of Veterinary Pathology, Seoul National University, Seoul, Republic of Korea.
Park KH; College of Veterinary Medicine, Department of Veterinary Pathology, Seoul National University, Seoul, Republic of Korea.
Chae C; College of Veterinary Medicine, Department of Veterinary Pathology, Seoul National University, Seoul, Republic of Korea.
Źródło:: Veterinary medicine and science [Vet Med Sci] 2021 May; Vol. 7 (3), pp. 755-765. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [Oxford] : John Wiley & Sons Ltd., [2015]-
MeSH Terms:: Bacterial Vaccines/*therapeutic use
Circoviridae Infections/*veterinary
Pneumonia of Swine, Mycoplasmal/*therapy
Vaccines, Combined/*therapeutic use
Viral Vaccines/*therapeutic use
Animals ; Circoviridae Infections/therapy ; Circoviridae Infections/virology ; Circovirus/immunology ; Mycoplasma hyopneumoniae/immunology ; Pneumonia of Swine, Mycoplasmal/microbiology ; Sus scrofa ; Swine ; Swine Diseases/therapy
References:: Prev Vet Med. 2013 Jun 1;110(2):88-102. (PMID: 23490147)
PLoS One. 2018 Dec 6;13(12):e0208585. (PMID: 30521609)
Virus Res. 2012 Mar;164(1-2):10-9. (PMID: 22056845)
Clin Vaccine Immunol. 2013 Mar;20(3):369-76. (PMID: 23302743)
Vet Pathol. 2004 Nov;41(6):624-40. (PMID: 15557072)
Vet Med Sci. 2021 May;7(3):755-765. (PMID: 33386664)
Vet J. 2005 May;169(3):326-36. (PMID: 15848776)
Virus Res. 2012 Mar;164(1-2):78-89. (PMID: 22178804)
J Comp Pathol. 2004 Aug-Oct;131(2-3):121-6. (PMID: 15276851)
Clin Vaccine Immunol. 2011 Oct;18(10):1644-9. (PMID: 21852549)
Viral Immunol. 2000;13(2):143-53. (PMID: 10892995)
Vet Microbiol. 2019 Apr;231:87-92. (PMID: 30955830)
Vet Microbiol. 2007 Apr 15;121(3-4):352-6. (PMID: 17276021)
Virus Res. 2009 Oct;145(1):151-6. (PMID: 19540280)
Prev Vet Med. 2013 Jun 1;110(2):103-18. (PMID: 23375866)
Clin Vaccine Immunol. 2011 Nov;18(11):1865-71. (PMID: 21940407)
Microbiol Mol Biol Rev. 1998 Dec;62(4):1094-156. (PMID: 9841667)
Vaccine. 2012 Dec 14;30(52):7625-9. (PMID: 23084853)
Vet J. 2012 Nov;194(2):151-7. (PMID: 22841450)
Vaccine. 2012 Oct 19;30(47):6671-7. (PMID: 22963801)
Vaccine. 2017 Jan 5;35(2):248-254. (PMID: 27919634)
J Comp Pathol. 2003 Jan;128(1):52-9. (PMID: 12531687)
Clin Vaccine Immunol. 2013 May;20(5):720-4. (PMID: 23486417)
Aust Vet J. 1997 Jul;75(7):504-11. (PMID: 9258425)
Vet Microbiol. 2004 Aug 19;102(1-2):55-65. (PMID: 15288927)
Vet J. 2014 Apr;200(1):65-70. (PMID: 24618398)
Arch Virol. 2014 Nov;159(11):3107-11. (PMID: 25034669)
J Gen Virol. 2015 Jul;96(Pt 7):1830-41. (PMID: 25711965)
Infect Genet Evol. 2015 Jul;33:320-3. (PMID: 26004195)
Vaccine. 2014 Jan 3;32(2):230-7. (PMID: 24269319)
Can J Vet Res. 2018 Jan;82(1):39-47. (PMID: 29382967)
Vet Pathol. 1995 Nov;32(6):648-60. (PMID: 8592800)
Am J Vet Res. 2000 Nov;61(11):1384-9. (PMID: 11108184)
Vet Microbiol. 2015 May 15;177(1-2):43-52. (PMID: 25790733)
Vet Microbiol. 2013 Apr 12;163(1-2):177-83. (PMID: 23305615)
Can J Vet Res. 2007 Jul;71(3):195-200. (PMID: 17695594)
Br Vet J. 1973 Sep-Oct;129(5):456-64. (PMID: 4770241)
Vaccine. 2016 Jan 4;34(2):270-275. (PMID: 26626212)
Transbound Emerg Dis. 2018 Apr;65(2):432-440. (PMID: 28963755)
Vaccine. 2009 Jun 19;27(30):4031-7. (PMID: 19379787)
Contributed Indexing:: Keywords: Mycoplasma hyopneumoniae; enzootic pneumonia; porcine circovirus type 2; porcine circovirus-associated disease; subclinical porcine circovirus type 2 infection
Substance Nomenclature:: 0 (Bacterial Vaccines)
0 (Vaccines, Combined)
0 (Viral Vaccines)
Entry Date(s):: Date Created: 20210102 Date Completed: 20211018 Latest Revision: 20211018
Update Code:: 20240105
PubMed Central ID:: PMC8136929
DOI:: 10.1002/vms3.420
PMID:: 33386664
: Czasopismo naukowe

Pełny tekst

Background: The field efficacy of a bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae was evaluated on three pig farms.
Methods: Three pig farms were used, two of which had a history of subclinical PCV2 and clinical M. hyopneumoniae infections between 84 and 126 days of age while concurrent porcine circovirus-associated disease and clinical M. hyopneumoniae infection between 70 and 105 days of age. Each farm vaccinated pigs with a single dose of a bivalent vaccine at 10 days of age while unvaccinated pigs were administered a single dose of phosphate buffered-saline at the same age.
Results: Vaccination improved growth performance and reduced clinical scores significantly (p < .05) when compared with unvaccinated animals. The amount of PCV2d loads in blood and M. hyopneumoniae loads in nasal swabs of vaccinated animals were also significantly lower (p < .05) when compared with unvaccinated animals. Immunologically, vaccinated groups elicited a significantly higher (p < .05) level of protective immunity against PCV2d such as neutralizing antibodies and interferon-γ secreting cells (IFN-γ-SC), as well as protective immunity against M. hyopneumoniae such as IFN-γ-SC when compared with unvaccinated animals. Pathologically, vaccination significantly lowered (p < .05) the scores of M. hyopneumoniae-induced pneumonia and PCV2-associated lymphoid lesions when compared with unvaccinated animals.
Conclusions: The evaluated bivalent vaccine provided good protection against PCV2d and M. hyopneumoniae infection under field conditions.
(© 2020 The Authors Veterinary Medicine and Science Published by John Wiley & Sons Ltd.)

Informacja